NCT05888493 2026-02-20
LEDA
Novartis
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT04094311 2026-02-17
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT05460533 2026-02-04
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03601442 2025-12-05
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Novartis
Available
NCT03568461 2025-10-07
ELARA
Novartis
Phase 2 Completed
NCT02445248 2024-04-18
JULIET
Novartis
Phase 2 Completed
NCT03876028 2023-01-31
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Novartis
Phase 1 Terminated
NCT04456023 2022-03-02
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Novartis
Phase 2 Withdrawn
NCT03123939 2021-07-21
Phase III B in Acute Lymphoblastic Leukemia
Novartis
Phase 3 Completed
NCT02228096 2020-11-23
ENSIGN
Novartis
Phase 2 Completed